GoAI
Get started
HeartBeam, Inc. logo

HeartBeam, Inc.

BEAT

NASDAQHealthcareMedical - Specialties

Open in GoAI

Previous close

$0.4933

+$0.015 · +3.14%

Aug 21, 4:00 PM ET

BEAT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

25

Expensive

Momentum

19

Strong Down

Sentiment

51

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.

Industry
Medical - Specialties
Sector
Healthcare
Headquarters
US
CEO
Robert Eno
Listed since
Nov 16, 2021
Employees
16

Market position

Day range

Current $0.4933

52-week range

Current $0.4933

Open
$0.4734
Previous close
$0.4783
Volume
210.1K
0.22× average
Average volume
946.37K
Average daily volume
Market cap
27.38M USD
Beta
-0.79
Market reference 1
50-day average
$0.5999
-17.77% below average
200-day average
$1.211
-59.27% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-0.95×
P/B (TTM)
3.18×
P/S (TTM)
0×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%

Financial health

Debt / equity
0×
Altman Z-score
-10.35
Piotroski F-score
2 of 9

Financial statements

Income trends

Operating income

−21.14M USD-6.30%

Net income

−21.02M USD-8.06%
Income trends across reported periods−399.6K USD−7.94M USD−15.48M USD−23.02M USDOperating income, FY2021: −2.29M USDOperating income, FY2022: −13.03M USDOperating income, FY2023: −15.31M USDOperating income, FY2024: −19.89M USDOperating income, FY2025: −21.14M USDNet income, FY2021: −4.43M USDNet income, FY2022: −12.96M USDNet income, FY2023: −14.64M USDNet income, FY2024: −19.45M USDNet income, FY2025: −21.02M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −2.29M USD. Operating income FY2022 −13.03M USD. Operating income FY2023 −15.31M USD. Operating income FY2024 −19.89M USD. Operating income FY2025 −21.14M USD. Net income FY2021 −4.43M USD. Net income FY2022 −12.96M USD. Net income FY2023 −14.64M USD. Net income FY2024 −19.45M USD. Net income FY2025 −21.02M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development13.45M USD11.05M USD6.8M USD5.68M USD255K USD
Selling, general, and administrative7.69M USD8.84M USD8.52M USD7.35M USD2.03M USD
Operating expenses21.14M USD19.89M USD15.31M USD13.03M USD2.29M USD
Interest income122K USD446K USD675K USD66K USD2.17K USD
Interest expense———66K USD2.17M USD
Depreciation and amortization40K USD7K USD15.31M USD13.03M USD—
Operating income−21.14M USD−19.89M USD−15.31M USD−13.03M USD−2.29M USD
Net income−21.02M USD−19.45M USD−14.64M USD−12.96M USD−4.43M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 7 misses, 0 met estimates
Average EPS surprise
-5.83%
11 comparable reports
Latest EPS result
-0.1
Estimate -0.09 · Miss by 16.28%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.07-0.13-0.18-0.23Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 13, 2025: actual -0.18, estimate -0.19, surprise +5.26%, Beat. Q2 2025, reported May 13, 2025: actual -0.18, estimate -0.15, surprise -20.00%, Miss. Q3 2025, reported Aug 13, 2025: actual -0.15, estimate -0.16, surprise +6.25%, Beat. Q4 2025, reported Nov 13, 2025: actual -0.15, estimate -0.16, surprise +6.25%, Beat. Q1 2026, reported Mar 12, 2026: actual -0.14, estimate -0.13, surprise -7.69%, Miss. Q2 2026, reported May 13, 2026: actual -0.12, estimate -0.14, surprise +14.29%, Beat. Q3 2026, reported Aug 13, 2026: actual -0.1, estimate -0.086, surprise -16.28%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.09, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.28M867.2K450.6K34KQ1 '24EstimateQ4 '25EstimateQ1 '26EstimateQ2 '26EstimateQ3 '26MissQ4 '26Estimate
Q1 2024, reported Mar 20, 2024: actual —, estimate 40K USD, surprise —, Comparison unavailable. Q4 2025, reported Nov 13, 2025: actual —, estimate 875K USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 12, 2026: actual —, estimate 1.19M USD, surprise —, Comparison unavailable. Q2 2026, reported May 13, 2026: actual —, estimate 149.75K USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 13, 2026: actual 100K USD, estimate 147.4K USD, surprise -32.16%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate 108.33K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

13 ratings
Strong buy00%
Buy969%
Hold431%
Sell00%
Strong sell00%

BEAT news

seekingalpha.com

HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript

HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript

Read source
businesswire.com

HeartBeam Reports Second Quarter 2026 Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Second Quarter 2026 Results.

Read source
businesswire.com

HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time.

Read source
zacks.com

Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now

Healthcare IT is emerging as AI's next growth story as providers adopt AI to cut costs & improve care. Here we present three stocks that are likely to benefit.

Read source
gurufocus.com

HeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG Device

[url="]HeartBeam, Inc.[/url] (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today an

Read source
zacks.com

Bet On These 5 Top-Ranked Stocks With Increasing P/E Ratios

Tap these five stocks, W, DHR, ISRG, BEAT and CSW, with rising P/E ratios to try out an out-of-the-box approach.

Read source

BEAT peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding BEAT

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
725.07K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
328.45K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
75.4K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research BEAT

research.disclaimer